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CORRESPONDENCE
Letters to the Editor
Assessing Risk After
Acute Myocardial Infarction
Mahmarian et al. (1) recently published the INSPIRE (AdenosINe
Sestamibi SPECT Post-InfaRction Evaluation) trial, a prospective
study comparing intensive medical therapy to revascularization in
stable patients following ST-segment elevation myocardial infarc-
tion (STEMI) or non-STEMI with demonstrable ischemic bur-
den on myocardial perfusion imaging (MPI). Medical therapy was
shown to be equivalent to revascularization, decreasing the ische-
mic burden at 2 months assessed by repeat MPI. The 1-year
clinical outcomes were also assessed, but the study was not
powered to detect any differences, and, predictably, did not.
Thus, medical therapy in stable patients with reversible perfu-
sion defects following an MI provided a short-term reduction in
ischemic burden comparable to that of revascularization. However,
although medical therapy may be comparable to revascularization
for improving inducible ischemia—or, as pointed out in the
accompanying editorial (2), “the heterogeneity of myocardial blood
flow induced by adenosine”—this does not mean that the strategies
are clinically equivalent. Inducible ischemia and clinical outcomes
do not necessarily go hand-in-hand.
The MPI was used to demonstrate “high-risk” anatomy; how-
ever, the trial excluded patients at high clinical risk who might
have benefited more from revascularization or patients who un-
derwent primary or early percutaneous revascularization for their
index event (a strategy many consider to be the treatment of
choice). Despite a “high-risk” perfusion study (performed an
average of 12 days after admission), patients in this study had
already declared themselves as being at relatively low clinical risk.
Furthermore, maximal medical therapy (excluding anti-
anginals) remains the standard of care for all patients with coronary
disease. In this trial, the treatment arms were not matched
regarding intensity of medical treatment. Patients in the medical-
therapy arm were more likely to be on dual-antiplatelet therapy
(aspirin/clopidogrel), lipid-lowering agents, and angiotensin-
converting enzyme (ACE) inhibitors. Patients who underwent
revascularization had the additional variable of less intensive
medical treatment. Few, if any, interventional cardiologists would
argue against the importance of intensive medical therapy post-
revascularization.
What we have learned from Mahmarian et al. (1) is that
intensive medical therapy has a greater impact on adenosine-
induced ischemia than previously appreciated. However, important
questions remain. The heterogeneous nature of the population is
never fully accounted for, but there may be real differences between
STEMI and NSTEMI patients. Additionally, 26 patients in the
medical therapy group were revascularized, and 24 patients in the
revascularization group were not; the reasons for this “crossover”
are not explained, and therefore the intention-to-treat analysis is
flawed.
The benefit of intensive medical therapy in patients following
an MI remains indisputable. However, a policy shift away from
early revascularization strategies in favor of MPI following an MI
is not supported by the INSPIRE study. Before utilizing MPI,
hard evidence supporting actual clinical benefit is needed.
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Reply
We appreciate the opportunity to re-emphasize the clinical mes-
sages from the (INSPIRE) trial (1,2). Patients at very high clinical
risk and those who had percutaneous coronary intervention (PCI)
for acute ST-segment elevation myocardial infarction (MI) were
excluded from INSPIRE because PCI is the preferred approach in
these settings. The INSPIRE cohort still represents 75% of
acute myocardial infarction (AMI) patients today who do not
receive acute PCI but who still are at substantial risk for subse-
quent events. In fact, 64% of our low Thrombolysis In Myocardial
Infarction (TIMI) risk-score patients had intermediate- or high-
risk scintigraphic characteristics resulting in a high 1-year event
rate of 15%.
The purpose of imaging is not only to stratify risk but also to
determine in whom risk can be reduced. The low- and
intermediate-risk groups in INSPIRE (which represented two-
thirds of all enrolled patients) would have unlikely benefited from
coronary revascularization owing to their low initial risk or lack of
inducible ischemia, respectively. The INSPIRE results comple-
ment the findings from the OAT (Occluded Artery Trial) (3),
which showed no advantage (and potential harm) from PCI and
stenting of occluded arteries post-AMI in patients who lacked
significant ischemia. Adenosine single-photon emission computed
tomography (SPECT) is a practical initial imaging method to
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